Business Context and Reporting Period
The filing is Nile Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2013, not Capricor Therapeutics or 2012 Q3 as indicated in the request metadata. Nile was a development-stage biopharmaceutical company developing cenderitide for heart failure and CU-NP, a preclinical cardiovascular and renal candidate. Neither product had generated commercial revenue.
Financial Performance and Position
| Metric | Three Months Ended March 31, 2013 | Three Months Ended March 31, 2012 |
|---|---|---|
| Total income | $0 | $195,500 |
| Research and development expense | $62,605 | $465,353 |
| General and administrative expense | $262,475 | $500,020 |
| Operating loss | $325,080 | $769,873 |
| Net loss | $482,763 | $771,879 |
| Basic and diluted loss per share | $0.01 loss | $0.02 loss |
| Cash used in operating activities | $144,184 | $603,460 |
| Cash provided by financing activities | $382,500 | $0 |
- Cash and cash equivalents were $285,032 at March 31, 2013, compared with $46,716 at December 31, 2012.
- Total assets were $415,308; total liabilities were $1.06 million; and stockholders’ deficit was $642,662.
- Current liabilities included $190,974 of notes payable, net of unamortized discount, and $408,842 of warrant liability.
- Working capital was negative approximately $245,000 at March 31, 2013, compared with negative approximately $159,000 at year-end 2012.
- The company had no product revenue and no meaningful operating margin; profitability metrics are not meaningful because the company remained pre-commercial and loss-making.
- Cash increased by $238,316 during the quarter, primarily from the March 2013 secured convertible-note financing, partly offset by operating cash use.
Material Changes Versus the Prior Comparable Period
- Total income declined to zero from $195,500 because the Medtronic collaboration was completed in February 2012 and generated no 2013 collaboration income.
- R&D expense decreased approximately 87% to $62,605 as clinical and other product-development activities were largely wound down.
- G&A expense decreased approximately 48% to $262,475, primarily from lower stock-based compensation and reduced professional fees.
- Net loss improved by approximately $289,000, although the company continued to incur losses.
- Operating cash use improved to $144,184 from $603,460, while financing provided $382,500 from the March 15, 2013 note issuance.
- The company issued secured convertible notes with $450,000 aggregate principal and $382,500 proceeds. The notes mature March 15, 2014, carry a 15% original issue discount, and are secured by a blanket lien.
- Warrant liability increased from $63,384 at December 31, 2012 to $408,842 at March 31, 2013, including the $203,400 fair value of warrants associated with the 2013 notes and a $142,058 noncash valuation expense.
Guidance, Outlook, Risks and Unusual Items
- Management stated that available cash was sufficient only to fund minimal operating expenses through the end of the second quarter of 2013.
- The company required substantial additional financing to continue operations and fund development. Management estimated a Phase 2 cenderitide trial would cost approximately $15 million to $20 million and take approximately 30 months.
- Cenderitide and CU-NP development activities were on hold pending additional financing or a strategic transaction. No collaboration partner or transaction had been secured.
- The filing stated that these conditions raised substantial doubt about the company’s ability to continue as a going concern. Management warned that failure to obtain capital could force the company to cease operations and wind down.
- The company was not in compliance with several Mayo license provisions, including annual maintenance-fee and active-development requirements. Amounts owed to Mayo totaled approximately $193,400, and failure to renegotiate could result in loss of rights to cenderitide and CU-NP.
- Deferred compensation accrued at March 31, 2013 included approximately $141,070 for the CEO and $45,633 for the CFO. Both executives reduced cash salaries to $100 per month pending an interim financing event.
- Potential future financing could cause substantial shareholder dilution, increase debt and interest obligations, or require unfavorable licensing arrangements.
- The company reported no material pending legal proceedings and no off-balance-sheet arrangements.
Most Important Facts to Verify
- Confirm the issuer and period: the supplied filing identifies Nile Therapeutics, Inc. and the quarter ended March 31, 2013, rather than Capricor Therapeutics or 2012 Q3.
- Verify whether the company obtained financing after the filing date sufficient to address the stated second-quarter 2013 cash runway and going-concern uncertainty.
- Verify the status of negotiations with Mayo and whether the cenderitide and CU-NP licenses remained in force.
- Review the terms, security interests, conversion provisions and change-of-control obligations of the March 2013 notes.
- Assess dilution from approximately 43.1 million common shares outstanding, 10.8 million outstanding warrants and 4.3 million outstanding stock options at March 31, 2013.
- Confirm whether development programs resumed, were partnered, or were discontinued after the reporting date.